All Episodes
|
69
|
John Marchica

Episode 69: Our Take, September 9, 2019

Sep 9, 2019

Episode Summary

In today’s Our Take read-in, here’s the lead: “A judge ordered Johnson & Johnson to pay $572 million to Oklahoma for creating a ‘public nuisance.’ The state had sought $17.5 billion in a lawsuit against J&J, contending that the company had engaged in misleading marketing and contributed to the opioid epidemic that has claimed the lives of more than 6,000 Oklahomans. J&J plans to appeal, and the company’s shares rose in after-hours trading on the day of the ruling, suggesting that investors believed the outcome could have been much worse.”

Episode Notes

In today’s Our Take read-in, here’s the lead: “A judge ordered Johnson & Johnson to pay $572 million to Oklahoma for creating a ‘public nuisance.’ The state had sought $17.5 billion in a lawsuit against J&J, contending that the company had engaged in misleading marketing and contributed to the opioid epidemic that has claimed the lives of more than 6,000 Oklahomans. J&J plans to appeal, and the company’s shares rose in after-hours trading on the day of the ruling, suggesting that investors believed the outcome could have been much worse.” To sign up for the weekly email brief, click here.

Other briefs include:

  • Capital Rx, a startup pharmacy benefit manager, launches its Clearinghouse Model.
  • A federal judge officially approves the merger between CVS Health and Aetna.
  • Michigan-based insurers Priority Health and Total Health Care will merge.
  • Amgen will buy Celgene’s Otezla (apremilast), a psoriasis drug, for $13.4 billion.
  • CMS rejects Idaho’s request for a waiver for Medicaid expansion.
  • Blue Cross and Blue Shield of Minnesota announcea 5-year, value-based agreement with Minnesota Oncology.

About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

⚙️ Health Care Rounds is produced by Grippi Media

Recommended Next

Podcast 216: When MisInformation Becomes a Health Crisis w/ Dr. Joshua Sharfstein, Johns Hopkins
Podcast 215: Real Health Care Happens Between Doctor Visits w/ Wei-Li Shao, President, Omada Health
Podcast 214: Mailbag: Debunking Vaccines Myths
Podcast 213: Health Care's Affordability Crisis Is Getting Worse w/ Larry Levitt, CEO-Elect & EVP, KFF
Podcast 212: Are We Measuring Health Care Quality All Wrong? w/ Dr. Rachel Werner, Professor of Medicine, UPenn
Podcast 211: The State of Value-Based Health Care w/ John Marchica, Darwin Research Group
Podcast 210: Why Health Care Reform Keeps Falling Short w/ Dr. Elliott Fisher, Dartmouth Institute
Podcast 209: Inside the Rural Health Transformation Program w/ Dr. Tim Ferris, InterSystems

Recommended Content

Browse Library
INsights
August 31, 2026

Darwin's Our Take 8.31.26: FDA grants momentous approval in pancreatic cancer

Read More
INsights
August 24, 2026

Darwin's Our Take 8.24.26: Moderna, Merck announce positive Phase III trial results for personalized mRNA cancer therapy

Read More
INsights
August 17, 2026

Darwin's Our Take 8.17.26: Trump tries again to revise federal childhood vaccination recommendations

Read More
Stay Aware. Stay Informed.

Subscribe to Our Take

Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.